hPG80: a Biomarker for Treatment Outcome Prediction

Interim data from our ongoing ONCOPRO prospective clinical study support the clinical utility of hPG80 as a potential new biomarker for immunotherapy outcome prediction in metastatic non-small cell lung cancer (NSCLC) patients.

​​

Key data were presented at the 2024 European Society for Medical Oncology Congress (Barcelona, Spain).​

 

Poster title: “Circulating hPG80 (WNT pathway activation) as a potential new prognostic/predictive factor of immunotherapy (ICI) efficacy: ONCOPRO prospective study”.​

 

In this study, the predictive value of hPG80 was assessed in a cohort of 45 patients with advanced NSCLC receiving either 1st line immunotherapy, alone or in combination with chemotherapy (n=21), or chemotherapy, alone or in combination with immunotherapy, regardless of the line of treatment (n=24). For these patients, hPG80 titers were determined at the initiation of treatment and at each treatment cycle. Patients were stratified into two groups: < or ≥ median at baseline and after 2 cycles of treatment and progression-free survival (PFS) was analyzed using the Kaplan-Meier method.

​​

As shown below, after 2 treatment cycles, for patients treated without immunotherapy in 1st line, hPG80 levels were not associated with improved PFS. However, in the cohort of patients receiving 1st line immunotherapy, patients with low hPG80 levels had a significantly longer PFS.